Rain Therapeutics Concludes Enrolment In Late-Stage Tissue Cancer Study, Expects Topline Data In H1 2023

Rain Therapeutics RAIN has completed patient enrolment in its Phase 3 MANTRA trial of its lead asset, milademetan for well-differentiated / dedifferentiated (WD/DD) liposarcoma (LPS).

The MANTRA study is a Phase 3 clinical trial evaluating milademetan compared to an approved standard of care in patients with well-differentiated / dedifferentiated (WD/DD) liposarcoma (LPS).

The trial aimed at enrolling about160 patients and completed enrollment five months ahead of schedule with 175 patients.

Liposarcoma is a rare cancer originating from fat cells located in the soft tissues of the body. It is a malignant cancer that can spread to other parts of the body. WD LPS is less aggressive and tends to be a large painless mass found in deeper tissues.

Avanish Vellanki, Co-founder and Chief executive officer, said, "We are excited to have achieved a milestone in our milademetan clinical program. We believe the rapid enrollment in MANTRA reflects a patient population in LPS that may be larger than expected, and that exhibits a significant unmet medical need.”

The company expects topline data readout from the Phase 3 clinical trial in the first half of 2023.

Price Action : Rain Therapeutics shares are trading low at $6.72 on Thursday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechHealth CareGeneralConcludes Enrolment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!